CRISIL Assigns 'Strong' ESG Rating of 61 to Aarti Drugs
Aarti Drugs Ltd 路 Others (Uncategorized) 路 09 Oct 2026, 12:51 am
CRISIL Assigns 'Strong' ESG Rating of 61 to Aarti Drugs Crisil ESG Ratings & Analytic Limited has assigned an Environmental, Social, and Governance (ESG) rating of 'Crisil ESG 61' (Strong) to Aarti Drugs Limited based on FY'26 data. The report, received by the company on 7th Oct'26, was prepared independently by the SEBI-registered Category-1 ESG rating provider using publicly available information without direct engagement from Aarti Drugs.
Original exchange filing (PDF)
More announcements from Aarti Drugs Ltd
- Intimation of sad demise of Promoter and Chairman Emeritus of the Company 路 16 Nov 2026
- Transcript of Q2&H1 FY27 Earning Conference call 路 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requireents) Regulations, 2015 路 06 Nov 2026
- Audio recording for conference call for Analyst and Investors 路 05 Nov 2026
- Investor Presentation for Q2 FY27 路 04 Nov 2026
- Press release on Financial results for Quarter and Half year ended September 2026 路 04 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 路 04 Nov 2026
- Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 04 Nov 2026
